Nothing Special   »   [go: up one dir, main page]

Bernat et al., 1996 - Google Patents

Antagonism of SR 90107A/Org 31540-lnduced Bleeding by Protamine Sulfate in Rats and Mice

Bernat et al., 1996

Document ID
9230876204564650832
Author
Bernat A
Hoffmann P
Herbert J
Publication year
Publication venue
Thrombosis and haemostasis

External Links

Snippet

The neutralization by protamine sulfate of bleeding enhancement induced by the potent anti- factor Xa pentasaccharide SR 90107A/Org 31540 and by heparin has been studied in rats and mice. Bleeding, as measured by transection of the tail of anaesthetised rats or mice, was …
Continue reading at www.thieme-connect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate

Similar Documents

Publication Publication Date Title
Thomas et al. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis
Van Ryn-McKenna et al. Neutralization of Enoxaparine-lnduced Bleeding by Protamine Sulfate
CA1194441A (en) Oligosaccharides having anti-xa activity process for obtaining them and pharmaceutical compositions containing them
DE69023957T2 (en) Sulphated polysaccharides, anticoagulants and anti-complementary agents made from brown algae fucans, and process for their manufacture.
CA2237159C (en) Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates
ES2242980T3 (en) DERMATAN DISULFATO, AN INHIBITOR OF THE THROMBIN GENERATION AND THE COMPLEMENT ACTIVATION.
Hirsh Low molecular weight heparin
Thomas et al. A low molecular weight heparin compared with unfractionated heparin
Herbert et al. SR123781A, a synthetic heparin mimetic
WO1980001383A1 (en) Heparin fragments having selective anticoagulation activity
US5922358A (en) Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications
US6075013A (en) Modified low molecular weight heparin that inhibits clot associated coagulation factors
JPH0216733B2 (en)
CA2377734A1 (en) Heparin compositions that inhibit clot associated coagulation factors
RU2153506C2 (en) Dermatan sulfate or its salt, antithrombotic agents, method of prophylaxis and treatment of thrombosis, method of prophylaxis or treatment of disseminated intravascular coagulation syndrome, method of myocardium infarction treatment
Bernat et al. Antagonism of SR 90107A/Org 31540-lnduced Bleeding by Protamine Sulfate in Rats and Mice
CH661439A5 (en) MODIFIED GLYCOSAMINOGLICANS EQUIPPED WITH ANTI-THROMBOTIC ACTIVITY.
Eika Anticoagulant and platelet aggregating activities of heparin
Iacoviello et al. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis
FI101152B (en) A process for the preparation of sulfated antithrombotic glycosaminoglycone uronan
Kaiser Anticoagulant and antithrombotic actions of recombinant hirudin
Persson et al. Plasma lipolytic activity after subcutaneous administration of heparin and a low molecular weight heparin fragment
KR960004021B1 (en) Anticoagulating substance and the preparation process thereof
Zhang et al. Improvement of patency in small veins following dextran and/or low-molecular-weight heparin treatment
Bernat et al. Protamine sulphate inhibits pentasaccharide (SR 80027)-induced bleeding without affecting its antithrombotic and anti-factor Xa activity in the rat